Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 6/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808935 | 0.88 | CYP1A2 (0.55) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL19341333 | 0.83 | CYP2A6 (0.59) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL10580788 | 0.82 | HTR2A (0.50) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL27962083 | 0.82 | CYP2A6 (0.57) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL17025295 | 0.81 | CYP1A2 (0.52) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL24080507 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL1510917 | 0.80 | SLC6A2 (0.57) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL24618315 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL8852223 | 0.80 | CYP2A6 (0.55) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL27962086 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2A6HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2022-01-06 | — | — | US | disclosed |
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2019-06-27 | — | — | US | disclosed |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-1308436-B1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-6916956-B2 | Calcium receptor antagonist | JAPAN TOBACCO, INC. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050107448-A1 | Calcium receptor antagonists | JAPAN TABACCO INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1288203-B1 | Cyclic nitrones and pharmaceutical compositions containing them | AVENTIS PHARMA INC (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20040006130-A1 | Calcium receptor antagonist | JAPAN TOBACCO INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308436-A1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1288203-A1 | Cyclic nitrones and pharmaceutical compositions containing them | Aventis Pharmaceuticals Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5962469-A | PREVENTION OF OXIDATION TISSUE DAMAGE BY FREE RADICALS | HOECHST MARION ROUSSEL INC. (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | CYP1A2 4829/4885CYP2A6 4283/4885HTR2A 4428/4885 |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | CYP1A2 4829/4885CYP2A6 4283/4885HTR2A 4428/4885 |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | CYP1A2 4829/4885CYP2A6 4283/4885HTR2A 4428/4885 |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | CYP1A2 4829/4885CYP2A6 4283/4885HTR2A 4428/4885 |
| US-20050107448-A1 | Calcium receptor antagonists | CASR, CALCR, CALCRL | CYP1A2 1943/4885CYP2A6 236/4885HTR2A 2300/4885 |
| US-20040006130-A1 | Calcium receptor antagonist | CALCRL, CASR, CALCR | CYP1A2 2060/4885CYP2A6 159/4885HTR2A 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.